352276-28-9 Usage
Description
Latanoprost Lactol, also known as (3aR,4R,5R,6aS)-Hexahydro-4-[(3R)-3-hydroxy-5-phenylpentyl]-2H-cyclopenta[b]furan-2,5-diol, is an intermediate compound in the synthesis of Latanoprost (L177280) related analogues. It is an F-series prostaglandin analog, which is a class of chemical compounds derived from prostaglandins, naturally occurring lipids with various physiological effects. Latanoprost Lactol is characterized by its unique chemical structure and plays a crucial role in the development of pharmaceuticals for the treatment of glaucoma and other degenerative eye diseases.
Uses
Used in Pharmaceutical Industry:
Latanoprost Lactol is used as an intermediate in the synthesis of Latanoprost, an F-series prostaglandin analog, for the treatment of glaucoma and various degenerative eye diseases. It helps in reducing intraocular pressure, which is a primary risk factor for glaucoma, and supports the development of effective pharmaceuticals to manage and prevent vision loss associated with these conditions.
Used in Ophthalmology:
In the field of ophthalmology, Latanoprost Lactol is used as a key component in the development of medications that address glaucoma and other eye diseases. Its role in the synthesis of Latanoprost-related analogues contributes to the creation of innovative treatments that can help preserve vision and improve the quality of life for patients suffering from these conditions.
Used in Research and Development:
Latanoprost Lactol is also utilized in research and development for the discovery and design of new pharmaceutical compounds with potential applications in the treatment of glaucoma and other eye diseases. Its unique chemical properties make it a valuable tool for scientists and researchers working to understand the mechanisms of these conditions and develop novel therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 352276-28-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,2,2,7 and 6 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 352276-28:
(8*3)+(7*5)+(6*2)+(5*2)+(4*7)+(3*6)+(2*2)+(1*8)=139
139 % 10 = 9
So 352276-28-9 is a valid CAS Registry Number.
InChI:InChI=1/C26H40O5.C13H12O3/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20;1-9(14)13(15)16-12-7-6-10-4-2-3-5-11(10)8-12/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3;2-9,14H,1H3/b8-3-;/t21-,22+,23+,24-,25+;/m0./s1
352276-28-9Relevant articles and documents
Asymmetric Synthesis of Corey Lactone and Latanoprost
Hayashi, Yujiro,Umekubo, Nariyoshi
supporting information, p. 6221 - 6227 (2020/09/21)
Corey lactone was synthesized in a single pot within 152 minutes in a 50 % overall yield via pot and time economical manner. Latanoprost, an antiglaucoma blockbuster drug, was also synthesized via seven pot reaction with five purifications in a 25 % total yield. One of the key reactions is asymmetric domino Michael/Michael reaction, formal [3+2] cycloaddition reaction, of 3-(dimethylphenylsilyl)propenal and ethyl 4-oxo-2-pentenoate, catalyzed by diphenylprolinol silyl ether, which constructed the core substituted cyclopentanone derivative with nearly optically pure form.
Compound And Method
-
, (2015/06/17)
A compound of formula (I): (I) wherein Y is, Z is OR10, NR11R11 SR11, S(0)R11 S02R11, R10 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, CO—R11, or a protecting group, and R11 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or alkoxyl; a process for making a compound of formula (I); and a process for making a prostaglandin or a prostaglandin analogue using a compound of formula (I). wherein Y is
Process for the synthesis of prostaglandins and intermediates thereof
-
, (2012/09/21)
A process is disclosed for the preparation of prostaglandins of the PGF2α-series, in particular Latanoprost, Bimatoprost and Travoprost, which are active in the treatment of ocular hypertensive conditions and glaucoma. The invention also relates to novel intermediates involved in the synthesis of these prostaglandin-PGF2α derivatives.
